Fennec Pharmaceuticals (FENC) Stock: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$10.96
-0.34 (-3.01%)
▼
5d:
-12.67%
30d:
-7.35%
90d:
+23.84%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: FENC is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: FENC is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$19.94
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$12.38
11.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $10.96, which is considered oversold relative to its 30-day fair value range of $11.22 to $12.32. The stock's valuation (Forward PE: 11.6) is in line with its historical norms (10.8). At these levels, the market is pricing in 2.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FENC is in a strong uptrend. The price is currently testing key support at $10.85. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: FENC scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.67 (+61.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FENC is in a strong uptrend. The price is currently testing key support at $10.85. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: FENC scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.67 (+61.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.22 -
$12.32
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 61.2% below Wall St target ($17.67)
- NEUTRAL: Market pricing in 2.3% annual earnings growth - fairly valued
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.22 -
$12.32
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.28
(11.7%)
Support & Resistance Levels
Support Level
$10.85
Resistance Level
$12.79
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.56
Wall Street Target
$17.67
(+61.2%)
Revenue Growth (YoY)
85.2%
Profit Margin
-5.5%
Valuation Premium vs History
+2.3% premium
PE vs Historical
11.6 vs 10.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.3%
(market-implied from PE analysis)
1-Year Target
$11.21
(+2%)
2-Year Target
$11.47
(+5%)
3-Year Target
$11.73
(+7%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$10.96
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 194.4%)
$64.53
(+489%)
Base:
(SPY PE: 11.6, Growth: 194.4%)
$36.99
(+238%)
Bear:
(PE: 9.8, Growth: 194.4%)
$31.44
(+187%)
Share & Embed Analysis
Last updated: September 13, 2026 10:23 AM ET
Data refreshes hourly during market hours. Next update: 11:23 AM
Data refreshes hourly during market hours. Next update: 11:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Rosty Raykov
SELL
10946 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
